143 related articles for article (PubMed ID: 36624315)
21. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Ri M; Suzuki K; Ishida T; Kuroda J; Tsukamoto T; Teshima T; Goto H; Jackson CC; Sun H; Pacaud L; Fujikawa E; Yeh TM; Hatayama T; Aida K; Sunagawa Y; Iida S
Cancer Sci; 2022 Dec; 113(12):4267-4276. PubMed ID: 36052883
[TBL] [Abstract][Full Text] [Related]
22. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
[TBL] [Abstract][Full Text] [Related]
23. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
24. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
25. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T; Usmani SZ; Berdeja JG; Agha M; Cohen AD; Hari P; Avigan D; Deol A; Htut M; Lesokhin A; Munshi NC; O'Donnell E; Stewart AK; Schecter JM; Goldberg JD; Jackson CC; Yeh TM; Banerjee A; Allred A; Zudaire E; Deraedt W; Olyslager Y; Zhou C; Pacaud L; Madduri D; Jakubowiak A; Lin Y; Jagannath S
J Clin Oncol; 2023 Feb; 41(6):1265-1274. PubMed ID: 35658469
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study.
Ying Z; Yang H; Guo Y; Li W; Zou D; Zhou D; Wang Z; Zhang M; Wu J; Liu H; Wang C; Ma L; Yang S; Zhou Z; Qin Y; Song Y; Zhu J
Cytotherapy; 2023 May; 25(5):521-529. PubMed ID: 36842849
[TBL] [Abstract][Full Text] [Related]
27. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells.
Ohkuri T; Wakita D; Chamoto K; Togashi Y; Kitamura H; Nishimura T
Br J Cancer; 2009 Apr; 100(7):1135-43. PubMed ID: 19277034
[TBL] [Abstract][Full Text] [Related]
29. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K
Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325
[TBL] [Abstract][Full Text] [Related]
31. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
32. Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4.
Jia ZC; Ni B; Huang ZM; Tian Y; Tang J; Wang JX; Fu XL; Wu YZ
Clin Dev Immunol; 2010; 2010():567594. PubMed ID: 21350607
[TBL] [Abstract][Full Text] [Related]
33. Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood.
Fan PW; Huang L; Chang XM; Feng YN; Yao X; Peng YC; Dong T; Wang RZ
Chin Med J (Engl); 2018 Jun; 131(11):1289-1295. PubMed ID: 29786040
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
Ying Z; Xie Y; Zheng W; Liu W; Lin N; Tu M; Wang X; Ping L; Deng L; Zhang C; Wu M; Feng F; Du T; Tang Y; Su F; Guo Z; Li J; Song Y; Zhu J
Bone Marrow Transplant; 2023 Mar; 58(3):288-294. PubMed ID: 36477110
[TBL] [Abstract][Full Text] [Related]
35. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
Saito T; Wada H; Yamasaki M; Miyata H; Nishikawa H; Sato E; Kageyama S; Shiku H; Mori M; Doki Y
Vaccine; 2014 Oct; 32(45):5901-7. PubMed ID: 25218300
[TBL] [Abstract][Full Text] [Related]
36. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
37. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.
Hont AB; Cruz CR; Ulrey R; O'Brien B; Stanojevic M; Datar A; Albihani S; Saunders D; Hanajiri R; Panchapakesan K; Darko S; Banerjee P; Fortiz MF; Hoq F; Lang H; Wang Y; Hanley PJ; Dome JS; Bollard CM; Meany HJ
J Clin Oncol; 2019 Sep; 37(26):2349-2359. PubMed ID: 31356143
[TBL] [Abstract][Full Text] [Related]
40. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
